Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy follow-up of CT-P6 vs trastuzumab in HER2-positive early breast cancer (CT-P6 4.2)
2019-003518-15Phase 4Completed
- Sponsor
- Celltrion
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of trastuzumab in breast cancer (2 arms), sponsored by Celltrion. Primary endpoints: Overall survival, Disease-free survival and 2 more. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-003518-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003518-15.